Our goal is to be a leading biopharmaceutical company discovering, developing and commercializing novel therapies that address some of the world's most widespread and costly chronic diseases. Important elements of our business strategy include:

• Advancing the development of our current clinical stage product candidates
  
  
• Continuing to expand our product pipeline with an emphasis on metabolic disease
  
  
• Continuing to enhance our liver-focused capabilities and intellectual property portfolio
  
  
• Pursuing a diversified development and commercialization strategy for our product candidates that balances risk but allows us to retain key commercial rights for building the business and shareholder value
  
  
• Establishing additional HepDirect partnerships with companies whose products would benefit from improved liver targeting, such as our collaboration with Merck
  
  
• Becoming an integrated pharmaceutical company by strategically building our internal development, regulatory and commercialization infrastructure as appropriate based on progress with our products and resources.